A relevant human Phase-I/II clinical trial (NCT04426669, NCT03538613) targeting CISH−/− TILs in combination with ICB-therapy was proposed by Intima Bioscience, UK, until 2021𠄲2022 against wide range of tumor types and gastrointestinal cancer [1,2,115] (Figure 8B,E, Table 3, Box-1). Here, CISH is linked to neoplasm.